Bishal Gyawali: The totality of evidence remains against routine adoption of adjuvant cdk4/6 as the default SOC

Bishal Gyawali, Associate Professor and Medical Oncologist at Queen’s University, shared a post by Mark Bolton, Radiation Oncologist on X, adding the following:

“This is a really good summary. Plus informative censoring and other adjuvant Cdk 4/6 trials with equally dubious results. The totality of evidence remains against routine adoption of adjuvant cdk4/6 as the default SOC. We discussed this in detail in our The Lancet Oncology essay, which still remains valid.”

Quoting Mark Bolton’s post:

“NATALEE: A good example of clinically insignificant ~3% benefit in a contrived endpoint at 3-years that jacks up toxicity, plus what happens at ~40 months? Hard to tell without CIs.”

Source: Bishal Gyawali/X and Mark Bolton/X